Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arthur J. Ammann is active.

Publication


Featured researches published by Arthur J. Ammann.


Growth Factors Journal | 1990

Recombinant Human Transforming Growth Factor—Beta 1 (rhTGF-β1) Enhances Healing and Strength of Granulation Skin Wounds

L. Steven Beck; Theresa L. Chen; Philip Mikalauski; Arthur J. Ammann

A new animal model to study secondary intention wound healing and the effects of topically applied rhTGF-beta 1 was developed. A time course study was performed of full thickness 6 mm punch wounds placed on the backs of anesthetized pigs and treated once with either 3% methylcellulose or rhTGF-beta 1 in 3% methylcellulose or left untreated. Wounds receiving rhTGF-beta 1 had enhanced tensile strength at days 4 and 7 compared to controls. Studies of the response on days 4 and 7 to graded doses of rhTGF-beta 1 showed that a dose of 250 or 2500 ng rhTGF-beta 1 gave a similar enhanced wound strength, while 25 ng rhTGF-beta 1 had no effect. Blood flow to treated granulating wounds as measured by 141Ce microspheres indicate an increase in flow in wounds treated with 250, 500 or 2500 ng rhTGF-beta 1 compared to controls. These results indicate a possible use for rhTGF-beta 1 in enhancing wound healing clinically.


Growth Factors Journal | 1990

Accelerated Healing of Ulcer Wounds in the Rabbit Ear by Recombinant Human Transforming Growth Factor-β1

L. Steven Beck; Theresa L. Chen; Sue E. Hirabayashi; Leo Deguzman; Wyne P. Lee; Lorrie McFATRIDGE; Yvette Xu; Rebecca L. Bates; Arthur J. Ammann

A dermal ulcer wound-healing model was established in rabbit ear to examine the effects of recombinant human transforming growth factor-beta 1 (rhTGF-beta 1) in wound healing. Histomorphometric examination of the wounds indicate a biphasic healing response 7 days after a single application of rhTGF-beta 1 at the time of wounding. Statistically significant healing occurred at 5-100 ng but not at higher doses of 500 or 1000 ng rhTGF-beta 1/wound. Enhanced collagen synthesis as determined by [3H]proline incorporation occurred at 15 and 25 ng and was significantly depressed at 500 ng rhTGF-beta 1/wound. Multiple doses of 100 ng rhTGF-beta 1 applied to the wound at the time of wounding and for 3 days after wounding provided results comparable to the single application of growth factor. Delaying treatment 24 hr after wounding did not enhance wound healing compared with vehicle. Our findings suggest that rhTGF-beta 1 can be a valuable growth factor to improve the healing of ulcer wounds.


The Journal of Pediatrics | 1992

Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection

Robert N. Husson; Yoomie Chung; Joyce Mordenti; Karina M. Butler; Sharon A. Chen; Anne-Marie Duliege; Pim Brouwers; Paul Jarosinski; Brigitta U. Mueller; Arthur J. Ammann; Philip A. Pizzo

To determine the safety and pharmacokinetics of recombinant soluble CD4 (sCD4) administered by continuous intravenous infusion to children with symptomatic human immunodeficiency virus type 1 infection, we conducted a phase I study at the National Cancer Institute. Three dose levels of sCD4 were evaluated: 100, 300, and 1000 micrograms/kg per day. After an initial 12 weeks of treatment with sCD4 alone, dideoxyinosine at a dose of 90 mg/m2 every 8 hours was added and subjects were observed for an additional 12 weeks. Combination therapy was continued in patients in whom it was well tolerated. In addition to toxicity and pharmacokinetic monitoring, surrogate markers of antiviral activity were evaluated. Eleven children were enrolled in the study. During the 12 weeks of treatment with sCD4 alone, and during subsequent sCD4 plus dideoxyinosine combination therapy, no significant toxic reaction attributable to sCD4 or dideoxyinosine was encountered. Low-level anti-CD4 antibodies developed in two patients. Steady-state sCD4 levels increased proportionately at higher doses. The CD4 cell counts and serum p24 antigen levels did not provide evidence of antiviral activity. We conclude that sCD4 was well tolerated at doses up to 1000 micrograms/kg per day when administered by continuous intravenous infusion; however, evidence of in vivo antiviral activity was not observed in this study.


Annals of the New York Academy of Sciences | 1990

Transforming Growth Factor‐β Effect on Soft Tissue Repair

Arthur J. Ammann; L. Steven Beck; Leo Deguzman; Sue E. Hirabayashi; Wyne P. Lee; Lorrie McFATRIDGE; Tue Nguyen; Yvette Xu; Thomas A. Mustoe

Previous studies have demonstrated that TGF-beta possesses many of the biologic properties necessary for acceleration of the normal wound healing process. We report that recombinant human TGF-beta 2 (rhuTGF-beta 1) increases wound strength and accelerates wound closure when applied topically to experimental wounds. Doses of 5 to 1,000 ng/wound increased wound strength in a dose-response manner and wound strength increase as high as 161% above control in the rat incisional wound model. Increased wound strength was observed as early as 3 days following rhuTGF-beta 1 application and continued to Day 28. In the rabbit ear ulcer model, acceleration of wound closure was observed following doses of 5 to 100 ng/wound applied a single topical application. No adverse effects of rhuTGF-beta 1 were observed. The amount of fibrous tissue, scar formation, and mitotic figures were not significantly greater than control. Epithelialization of rhuTGF-beta 1-treated wounds was not impeded. rhuTGF-beta 1 induced bone formation in the rabbit ear ulcer model but not in the rat incisional model, suggesting that precursor cells, such as perichondrial cells, are required for the bone forming activities of TGF-beta 1.


Clinical Immunology and Immunopathology | 1989

Interleukin 2 responsive lymphocytes in patients with adenosine deaminase deficiency.

Morton J. Cowan; Wayne Smith; Arthur J. Ammann

We evaluated the effects of recombinant interleukin 2 (IL-2) on the proliferative responses to mitogens of peripheral blood mononuclear cells (PBMC) from three adenosine deaminase (ADA)-deficient patients. There was significant enhancement by IL-2 of the proliferative responses to phytohemagglutinin (PHA) and pokeweed mitogen (PWM) of PBMC from all three patients. We found that normal PBMC respond with increased numbers of CD3-positive cells when exposed to PHA or PWM and that the response by normal CD8-positive cells was greater than that by CD4-positive cells. In contrast, we found that in ADA-deficient cells the response is almost entirely due to the CD3/CD4-positive population of lymphocytes. These results could not be explained by either the culture conditions or the possibility of a mixed chimeric state. When we evaluated an in vitro cell model of ADA deficiency using an ADA inhibitor, erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), we found that the inhibitory effect of EHNA plus deoxyadenosine on mitogen-stimulated PBMC could not be prevented by IL-2. These results suggest that the immunodeficiency in ADA deficiency includes the absence or failure of a subset of T cells to make IL-2 and the failure of the CD8-positive subset to respond to IL-2. Also, the in vitro cell model of ADA deficiency using EHNA as the ADA inhibitor is limited in its use in understanding the pathogenesis of this disease.


Archive | 1989

Method of inducing bone growth using TGF-β

Arthur J. Ammann; Christopher G. Rudman


Archive | 1994

Tgf-beta formulation for inducing bone growth.

Arthur J. Ammann; Steven L. Beck; Tue H. Nguyen; Boonsri Ongpipattanakul; Christopher G. Rudman


Journal of Bone and Mineral Research | 2009

In vivo induction of bone by recombinant human transforming growth factor β1

L. Steven Beck; Arthur J. Ammann; Thomas B. Aufdemorte; Leo Deguzman; Yvette Xu; Wyne P. Lee; Lorrie A. McFatridge; Theresa L. Chen


Archive | 1988

Methods and compositions for the treatment of lung conditions

Arthur J. Ammann


Archive | 1994

TGF-βformulation for inducing bone growth

Arthur J. Ammann; Steven L. Beck; Tue H. Nguyen; Boonsri Ongpipattanakul; Christopher G. Rudman

Collaboration


Dive into the Arthur J. Ammann's collaboration.

Researchain Logo
Decentralizing Knowledge